This video is not available for purchase in your country.

Dasatinib leukaemia drug action

K003/2146

Rights Managed

  • {{ default.width }}x{{ default.height }}
  • {{ default.frame_rate }}
  • {{ default.size }}

This video is not available for purchase in your country.

Please contact your Account Manager if you have any query.

Credit

RAMON ANDRADE 3DCIENCIA / SCIENCE PHOTO LIBRARY RAMON ANDRADE 3DCIENCIA / SCIENCE PHOTO LIBRARY

Caption

Dasatinib leukaemia drug binding to its target, the enzyme Bcr-Abl tyrosine kinase. This enzyme is produced by a genetic mutation, the swapping of parts of two chromosomes, leading to the formation of the oncogene (cancer-causing gene) Bcr-Abl, which produces a constantly-active version of normal Abl tyrosine kinase. This causes chronic myelogenous leukaemia (CML), a cancer of white blood cells. The drug Sprycel (Dasatinib) works by binding to the active site of the Bcr-Abl enzyme, producing a change in shape that prevents the enzyme from functioning. This causes the death of cancerous cells expressing the enzyme. Sprycel is marketed by Bristol-Myers Squibb.

Release details

Model release not required. Property release not required.

Downloadable Master

  • Duration: 00:00:10
  • Audio: No
  • Format: Photo - JPEG

Original

  • Capture Format: QuickTime Animation
  • Codec: None
  • Interlaced: Yes
  • Frame Size: 1920 x 1080

Contact us if you require the original or other formats.

 {{ i.shot_duration ? i.shot_duration + ' ' : '' }}{{ i.shot_uhd ? '4K ' : i.hires ? 'HD ' : '' }}{{ i.spl_number }} R{{ i.license }}

  • Calculate price
  • Add to board